Evidence map›Paper›PMID 36647720›Full record

ArticleActa biochimica et biophysica Sinica2022

COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer.

Zhiyang Zhou, Li Jin, Jian Shen, Weihui Shi, Yue Xu, Longyun Ye, Junxi Liu, Jiexue Pan

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Zhiyang ZhouObstetrics & Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200011, China.
Li JinObstetrics & Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200011, China.
Jian ShenCollege of Life Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Weihui ShiObstetrics & Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200011, China.
Yue XuObstetrics & Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200011, China.
Longyun YeDepartment of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Junxi LiuChinese Academy of Science Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, China.
Jiexue PanObstetrics & Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai 200011, China.
Obstetrics and Gynecology Hospital of Fudan University · CNShanghai Medical College of Fudan University · CNZhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite favorable responses to platinum-based chemotherapy in ovarian cancer (OC), chemoresistance is still a major cause of treatment failure. Hence, we develop a novel synthetic agent, COM33, to relieve the chemoresistance caused by carboplatin. The anti-cancerous effects of the combination of COM33 and carboplatin on OC are evaluated by cell viability, wound healing, and transwell invasion assays. A mechanistic investigation is carried out by using RNA-Seq analysis and then verified by western blot analysis and immunofluorescence microscopy. The safety and efficacy

Indexed as

Drug Resistance, NeoplasmEpithelial-Mesenchymal TransitionOvarian NeoplasmsTwist-Related Protein 1AnimalsAntineoplastic AgentsAporphinesCarboplatinCell Line, TumorCell MovementCell ProliferationCell SurvivalFemaleHumansMiceMice, NudeAntineoplastic AgentsAporphinesCarboplatinCOM33Twist-Related Protein 1carboplatinCOM33epithelial-mesenchymal transitionovarian cancerTwist1

Identifiers

PMID36647720
PMCPMC10157527
OpenAlexW4311866300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.